Header Logo

Connection

Christopher Goetz to Humans

Back to Details
This is a "connection" page, showing publications Christopher Goetz has written about Humans.
Christopher Goetz
Connection Strength
3.232
Humans
  1. Reply to: "The Framework for Diagnostic Criteria in Movement Disorders: The Value of Methodological Tools and Combined Criteria". Mov Disord. 2023 09; 38(9):1763-1764.
    View in: PubMed
    Score: 0.048
  2. Reply to: Comment on "Summing MDS-UPDRS Parts 1?+?2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice". Mov Disord. 2023 08; 38(8):1564.
    View in: PubMed
    Score: 0.047
  3. It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum. Mov Disord. 2023 02; 38(2):342-347.
    View in: PubMed
    Score: 0.045
  4. The plight of loneliness in Parkinson's disease: New opportunities. Parkinsonism Relat Disord. 2022 Dec; 105:145-148.
    View in: PubMed
    Score: 0.045
  5. Reply to: Cognitive Effects of Deep Brain Stimulation in GBA-Related Parkinson's Disease. Ann Neurol. 2022 08; 92(2):345-346.
    View in: PubMed
    Score: 0.044
  6. Two faces of the teacher: Comparing editions of Charcot's Le?ons du mardi. J Hist Neurosci. 2022 Oct-Dec; 31(4):512-523.
    View in: PubMed
    Score: 0.043
  7. Implementation and Outcomes of a Movement Disorder Society-Sponsored Peer Reviewing Education and Mentoring Program. Mov Disord. 2022 05; 37(5):1093-1097.
    View in: PubMed
    Score: 0.043
  8. Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Ann Neurol. 2022 03; 91(3):424-435.
    View in: PubMed
    Score: 0.043
  9. Is Telemedicine the New Normal or Is the Office Visit Still the Movement Disorder Option of Choice? Mov Disord. 2021 07; 36(7):1481-1482.
    View in: PubMed
    Score: 0.041
  10. Apathy in Parkinson disease: Why we should care. Neurology. 2020 11 17; 95(20):893-894.
    View in: PubMed
    Score: 0.039
  11. The Evolution-Driven Signature of Parkinson's Disease. Trends Neurosci. 2020 07; 43(7):475-492.
    View in: PubMed
    Score: 0.038
  12. Movement Disorder Society-Unified Parkinson's Disease Rating Scale Use in the Covid-19 Era. Mov Disord. 2020 06; 35(6):911.
    View in: PubMed
    Score: 0.038
  13. Parkinson's disease: Is it a consequence of human brain evolution? Mov Disord. 2019 04; 34(4):453-459.
    View in: PubMed
    Score: 0.035
  14. What influences placebo and nocebo responses in Parkinson's disease? Mov Disord. 2018 08; 33(8):1204-1212.
    View in: PubMed
    Score: 0.034
  15. Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Mov Disord. 2018 07; 33(7):1189-1190.
    View in: PubMed
    Score: 0.033
  16. Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years? Mov Disord. 2017 12; 32(12):1651-1652.
    View in: PubMed
    Score: 0.032
  17. Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. Mov Disord. 2017 09; 32(9):1335-1336.
    View in: PubMed
    Score: 0.031
  18. Differential item functioning in the Unified Dyskinesia Rating Scale (UDysRS). Mov Disord. 2017 Aug; 32(8):1244-1249.
    View in: PubMed
    Score: 0.031
  19. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. Mov Disord. 2016 12; 31(12):1865-1873.
    View in: PubMed
    Score: 0.030
  20. Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease. Mov Disord. 2016 Jan; 31(1):11-22.
    View in: PubMed
    Score: 0.028
  21. Preface. Mov Disord. 2015 Sep 15; 30(11):1441.
    View in: PubMed
    Score: 0.027
  22. Handling missing values in the MDS-UPDRS. Mov Disord. 2015 Oct; 30(12):1632-8.
    View in: PubMed
    Score: 0.026
  23. Initial management of Parkinson's disease. BMJ. 2014 Dec 19; 349:g6258.
    View in: PubMed
    Score: 0.026
  24. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Parkinsonism Relat Disord. 2014 Nov; 20(11):1135-9.
    View in: PubMed
    Score: 0.025
  25. Maynard M. Cohen, MD, PhD (1920-2014). Neurology. 2014 Jun 03; 82(22):1944-5.
    View in: PubMed
    Score: 0.025
  26. Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. Mov Disord. 2014 Sep; 29(10):1252-7.
    View in: PubMed
    Score: 0.025
  27. Are patients with Parkinson's disease blind to blindsight? Brain. 2014 Jun; 137(Pt 6):1838-49.
    View in: PubMed
    Score: 0.025
  28. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain. 2014 Mar; 137(Pt 3):849-59.
    View in: PubMed
    Score: 0.024
  29. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. Mov Disord. 2014 Jan; 29(1):115-7.
    View in: PubMed
    Score: 0.024
  30. Treating melancholia at home: theoretical wisdom and grim reality in the career of E.C. Seguin. Neurology. 2013 Apr 30; 80(18):1710-4.
    View in: PubMed
    Score: 0.023
  31. The Parkinson's disease multidisciplinary package. Mov Disord. 2013 May; 28(5):565.
    View in: PubMed
    Score: 0.023
  32. Which dyskinesia scale best detects treatment response? Mov Disord. 2013 Mar; 28(3):341-6.
    View in: PubMed
    Score: 0.023
  33. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov Disord. 2012 Sep 01; 27(10):1239-42.
    View in: PubMed
    Score: 0.022
  34. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). J Neurol. 2013 Jan; 260(1):228-36.
    View in: PubMed
    Score: 0.022
  35. Clinical differences among mild cognitive impairment subtypes in Parkinson's disease. Mov Disord. 2012 Aug; 27(9):1129-36.
    View in: PubMed
    Score: 0.022
  36. Tai chi for patients with Parkinson's disease. N Engl J Med. 2012 05 03; 366(18):1737-8; author reply 1738.
    View in: PubMed
    Score: 0.022
  37. Vibration therapy for Parkinson's disease: Charcot's studies revisited. J Parkinsons Dis. 2012; 2(1):23-7.
    View in: PubMed
    Score: 0.021
  38. Clinical validation of Movement Disorder Society-recommended diagnostic criteria for Parkinson's disease with dementia. Mov Disord. 2012 Feb; 27(2):248-53.
    View in: PubMed
    Score: 0.021
  39. Dopamine dysregulation syndrome item from the MDS-UPDRS. Mov Disord. 2012 Jan; 27(1):166.
    View in: PubMed
    Score: 0.021
  40. Temporal stability of the Unified Dyskinesia Rating Scale. Mov Disord. 2011 Dec; 26(14):2556-9.
    View in: PubMed
    Score: 0.021
  41. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011 Sep; 1(1):a008862.
    View in: PubMed
    Score: 0.021
  42. Wearing-off scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Oct; 26(12):2169-75.
    View in: PubMed
    Score: 0.021
  43. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord. 2011 Oct; 26(12):2196-200.
    View in: PubMed
    Score: 0.021
  44. An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opin Pharmacother. 2011 Sep; 12(13):2009-24.
    View in: PubMed
    Score: 0.020
  45. The movement disorder society and movement disorders: a modern history. Mov Disord. 2011 May; 26(6):939-46.
    View in: PubMed
    Score: 0.020
  46. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
    View in: PubMed
    Score: 0.020
  47. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Dec 15; 25(16):2704-16.
    View in: PubMed
    Score: 0.020
  48. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010 Nov 16; 75(20):1773-9.
    View in: PubMed
    Score: 0.019
  49. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
    View in: PubMed
    Score: 0.019
  50. Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Jul 15; 25(9):1131-42.
    View in: PubMed
    Score: 0.019
  51. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010 Jul 15; 25(9):1190-4.
    View in: PubMed
    Score: 0.019
  52. Shaking up the Salpetriere: Jean-Martin Charcot and mercury-induced tremor. Neurology. 2010 May 25; 74(21):1739-42.
    View in: PubMed
    Score: 0.019
  53. Chapter 15: Jean-Martin Charcot and the anatomo-clinical method of neurology. Handb Clin Neurol. 2010; 95:203-12.
    View in: PubMed
    Score: 0.018
  54. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S104-9.
    View in: PubMed
    Score: 0.018
  55. Scales to evaluate psychosis in Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S38-41.
    View in: PubMed
    Score: 0.018
  56. Charcot and Pasteur: intersecting orbits in fin de si?cle French medicine. J Hist Neurosci. 2009 Oct; 18(4):378-86.
    View in: PubMed
    Score: 0.018
  57. Jean-Martin Charcot and his vibratory chair for Parkinson disease. Neurology. 2009 Aug 11; 73(6):475-8.
    View in: PubMed
    Score: 0.018
  58. Teaching program for the Unified Dyskinesia Rating Scale. Mov Disord. 2009 Jul 15; 24(9):1296-8.
    View in: PubMed
    Score: 0.018
  59. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009 Jun; 5(6):331-42.
    View in: PubMed
    Score: 0.018
  60. Determinants of quality of life in children with Gilles de la Tourette syndrome. Mov Disord. 2009 May 15; 24(7):1070-3.
    View in: PubMed
    Score: 0.018
  61. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation--critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord. 2009 Apr 15; 24(5):635-46.
    View in: PubMed
    Score: 0.018
  62. Movement disorders caused by medical disease. Semin Neurol. 2009 Apr; 29(2):97-110.
    View in: PubMed
    Score: 0.018
  63. Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Mov Disord. 2009 Mar 15; 24(4):551-6.
    View in: PubMed
    Score: 0.017
  64. Comparison of tic characteristics between children and adults. Mov Disord. 2008 Dec 15; 23(16):2407-11.
    View in: PubMed
    Score: 0.017
  65. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord. 2008 Dec 15; 23(16):2398-403.
    View in: PubMed
    Score: 0.017
  66. Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol. 2008 Dec; 64 Suppl 2:S81-92.
    View in: PubMed
    Score: 0.017
  67. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.017
  68. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008 Oct 30; 23(14):2004-14.
    View in: PubMed
    Score: 0.017
  69. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008 Oct 30; 23(14):2015-25.
    View in: PubMed
    Score: 0.017
  70. The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology. 2008 Aug 26; 71(9):677-84.
    View in: PubMed
    Score: 0.017
  71. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
    View in: PubMed
    Score: 0.017
  72. Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments. Mov Disord. 2008 Jul 30; 23(10):1479-82.
    View in: PubMed
    Score: 0.017
  73. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
    View in: PubMed
    Score: 0.017
  74. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord. 2008 Apr 15; 23(5):700-7.
    View in: PubMed
    Score: 0.016
  75. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008 Apr 15; 23(5):690-9.
    View in: PubMed
    Score: 0.016
  76. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008 Mar 15; 23(4):484-500.
    View in: PubMed
    Score: 0.016
  77. Concerning about the accuracy of data reported. Mov Disord. 2008 Mar 15; 23(4):473; author reply 473.
    View in: PubMed
    Score: 0.016
  78. Disclosure on author work effort. Mov Disord. 2007 Oct 31; 22(14):1989.
    View in: PubMed
    Score: 0.016
  79. Levodopa-induced dyskinesias. Mov Disord. 2007 Jul 30; 22(10):1379-1389.
    View in: PubMed
    Score: 0.016
  80. J.-M. Charcot and simulated neurologic disease: attitudes and diagnostic strategies. Neurology. 2007 Jul 03; 69(1):103-9.
    View in: PubMed
    Score: 0.016
  81. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007 Jun 15; 22(8):1061-8.
    View in: PubMed
    Score: 0.015
  82. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15; 22(8):1077-92.
    View in: PubMed
    Score: 0.015
  83. Contribution of Jules Froment to the study of parkinsonian rigidity. Mov Disord. 2007 May 15; 22(7):909-14.
    View in: PubMed
    Score: 0.015
  84. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007 Jan 15; 22(2):179-86.
    View in: PubMed
    Score: 0.015
  85. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.015
  86. Early cinematographic studies of generalized dystonia. Mov Disord. 2006 Oct; 21(10):1561-5.
    View in: PubMed
    Score: 0.015
  87. Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations. BMC Med Res Methodol. 2006 Jun 13; 6:26.
    View in: PubMed
    Score: 0.014
  88. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
    View in: PubMed
    Score: 0.014
  89. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
    View in: PubMed
    Score: 0.014
  90. Charcot in contemporary literature. J Hist Neurosci. 2006 Mar; 15(1):22-30.
    View in: PubMed
    Score: 0.014
  91. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
    View in: PubMed
    Score: 0.014
  92. Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Apr; 12(3):177-80.
    View in: PubMed
    Score: 0.014
  93. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005 May; 20(5):523-39.
    View in: PubMed
    Score: 0.013
  94. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
    View in: PubMed
    Score: 0.013
  95. Movement disorders: understanding clinical trials. Lancet Neurol. 2005 Jan; 4(1):5-6.
    View in: PubMed
    Score: 0.013
  96. Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol. 2005 Jan; 57(1):144-7.
    View in: PubMed
    Score: 0.013
  97. Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape. Mov Disord. 2004 Dec; 19(12):1453-6.
    View in: PubMed
    Score: 0.013
  98. Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. Parkinsonism Relat Disord. 2004 Dec; 10(8):507-10.
    View in: PubMed
    Score: 0.013
  99. Medical-legal issues in Charcot's neurologic career. Neurology. 2004 May 25; 62(10):1827-33.
    View in: PubMed
    Score: 0.013
  100. Re: UPDRS: Status and recommendations. Mov Disord. 2004 May; 19(5):605.
    View in: PubMed
    Score: 0.012
  101. Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord. 2003 Dec; 18(12):1455-8.
    View in: PubMed
    Score: 0.012
  102. Wheeled and standard walkers in Parkinson's disease patients with gait freezing. Parkinsonism Relat Disord. 2003 Oct; 10(1):9-14.
    View in: PubMed
    Score: 0.012
  103. Impact of placebo assignment in clinical trials of Parkinson's disease. Mov Disord. 2003 Oct; 18(10):1146-9.
    View in: PubMed
    Score: 0.012
  104. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord. 2003 Jul; 18(7):831-2.
    View in: PubMed
    Score: 0.012
  105. Pierre Marie: gifted intellect, poor timing and unchecked emotionality. J Hist Neurosci. 2003 Jun; 12(2):154-66.
    View in: PubMed
    Score: 0.012
  106. A Unified Framework for Evidence-Based Diagnostic Criteria Programs in Movement Disorders. Mov Disord. 2023 07; 38(7):1156-1162.
    View in: PubMed
    Score: 0.012
  107. Understanding visual hallucinations: A new synthesis. Neurosci Biobehav Rev. 2023 07; 150:105208.
    View in: PubMed
    Score: 0.012
  108. Tremor and ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol. 2003 May; 53(5):616-23.
    View in: PubMed
    Score: 0.012
  109. Summing MDS-UPDRS Parts 1?+?2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice. Mov Disord. 2023 07; 38(7):1363-1364.
    View in: PubMed
    Score: 0.012
  110. The prefaces by Charcot: leitmotifs of an international career. Neurology. 2003 Apr 22; 60(8):1333-40.
    View in: PubMed
    Score: 0.012
  111. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003 Apr; 60(4):529-33.
    View in: PubMed
    Score: 0.012
  112. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology. 2003 Mar 25; 60(6):917-22.
    View in: PubMed
    Score: 0.012
  113. An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson's disease participants. Nat Commun. 2023 02 18; 14(1):926.
    View in: PubMed
    Score: 0.011
  114. Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease. Mov Disord. 2023 04; 38(4):688-692.
    View in: PubMed
    Score: 0.011
  115. Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings. Mov Disord. 2023 03; 38(3):453-463.
    View in: PubMed
    Score: 0.011
  116. Treatment of advanced Parkinson's disease: an evidence-based analysis. Adv Neurol. 2003; 91:213-28.
    View in: PubMed
    Score: 0.011
  117. History of the extensor plantar response: Babinski and Chaddock signs. Semin Neurol. 2002 Dec; 22(4):391-8.
    View in: PubMed
    Score: 0.011
  118. Jean-Martin Charcot and the aging brain. Arch Neurol. 2002 Nov; 59(11):1821-4.
    View in: PubMed
    Score: 0.011
  119. Intestinal microbiota and neuroinflammation in Parkinson's disease: At the helm of the gut-brain axis. Int Rev Neurobiol. 2022; 167:81-99.
    View in: PubMed
    Score: 0.011
  120. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002 Aug; 59(8):1249-52.
    View in: PubMed
    Score: 0.011
  121. Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling. Mov Disord. 2022 09; 37(9):1904-1914.
    View in: PubMed
    Score: 0.011
  122. Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. Mov Disord. 2022 08; 37(8):1749-1755.
    View in: PubMed
    Score: 0.011
  123. Gut microbial metabolites in Parkinson's disease: Association with lifestyle, disease characteristics, and treatment status. Neurobiol Dis. 2022 08; 170:105780.
    View in: PubMed
    Score: 0.011
  124. Gut-Brain Communication in Parkinson's Disease: Enteroendocrine Regulation by GLP-1. Curr Neurol Neurosci Rep. 2022 07; 22(7):335-342.
    View in: PubMed
    Score: 0.011
  125. Therapies for movement disorders. Arch Neurol. 2002 May; 59(5):699-702.
    View in: PubMed
    Score: 0.011
  126. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord. 2002 Mar; 17(2):283-8.
    View in: PubMed
    Score: 0.011
  127. Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Mov Disord. 2022 04; 37(4):826-841.
    View in: PubMed
    Score: 0.011
  128. Rating scales for medication adherence in people living with Parkinson's disease: a systematic review protocol. JBI Evid Synth. 2022 01 01; 20(1):260-269.
    View in: PubMed
    Score: 0.011
  129. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. JAMA. 2021 09 14; 326(10):926-939.
    View in: PubMed
    Score: 0.010
  130. Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change. Mov Disord. 2021 12; 36(12):2853-2861.
    View in: PubMed
    Score: 0.010
  131. Validation of the Finnish Version of the Unified Dyskinesia Rating Scale. Eur Neurol. 2021; 84(6):444-449.
    View in: PubMed
    Score: 0.010
  132. Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia? Tremor Other Hyperkinet Mov (N Y). 2021 06 23; 11:21.
    View in: PubMed
    Score: 0.010
  133. Validation of the Polish version of the Unified Dyskinesia Rating Scale (UDysRS). Neurol Neurochir Pol. 2021; 55(2):186-194.
    View in: PubMed
    Score: 0.010
  134. Head tremor and pain in cervical dystonia. J Neurol. 2021 May; 268(5):1945-1950.
    View in: PubMed
    Score: 0.010
  135. In Support of Electronic Versions of Movement Disorder Society Rating Scales. Mov Disord. 2021 01; 36(1):270-271.
    View in: PubMed
    Score: 0.010
  136. COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel? J Parkinsons Dis. 2021; 11(1):3-8.
    View in: PubMed
    Score: 0.010
  137. It's tricky: Rating alleviating maneuvers in cervical dystonia. J Neurol Sci. 2020 Dec 15; 419:117205.
    View in: PubMed
    Score: 0.010
  138. Efficacy, tolerability, and safety of an innovative medical device for improving oral accessibility during oral examination in special-needs patients: A multicentric clinical trial. PLoS One. 2020; 15(9):e0239898.
    View in: PubMed
    Score: 0.010
  139. Validation of the Polish version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Neurol Neurochir Pol. 2020; 54(5):416-425.
    View in: PubMed
    Score: 0.010
  140. Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale. Neuroepidemiology. 2020; 54(4):356-362.
    View in: PubMed
    Score: 0.010
  141. Item Response Theory Analysis of the MDS-UPDRS Motor Examination: Tremor vs. Nontremor Items. Mov Disord. 2020 09; 35(9):1587-1595.
    View in: PubMed
    Score: 0.009
  142. Postural Directionality and Head Tremor in Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2020; 10.
    View in: PubMed
    Score: 0.009
  143. The Progressive Supranuclear Palsy Clinical Deficits Scale. Mov Disord. 2020 04; 35(4):650-661.
    View in: PubMed
    Score: 0.009
  144. Preface. Int Rev Neurobiol. 2020; 153:xi-xii.
    View in: PubMed
    Score: 0.009
  145. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019 10 01; 93(14):e1328-e1338.
    View in: PubMed
    Score: 0.009
  146. Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration. Parkinsonism Relat Disord. 2019 10; 67:113-116.
    View in: PubMed
    Score: 0.009
  147. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. Mov Disord. 2019 06; 34(6):791-798.
    View in: PubMed
    Score: 0.009
  148. The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. Mov Disord. 2019 05; 34(5):676-681.
    View in: PubMed
    Score: 0.009
  149. Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2018 10; 33(10):1601-1608.
    View in: PubMed
    Score: 0.008
  150. Movement disorder society criteria for clinically established early Parkinson's disease. Mov Disord. 2018 10; 33(10):1643-1646.
    View in: PubMed
    Score: 0.008
  151. Visibility and Depth of the Stromal Demarcation Line After Corneal Collagen Cross-Linking Using Anterior Segment Optical Coherence Tomography: Comparison Between Isoosmolar and Hypoosmolar Riboflavin. Cornea. 2018 May; 37(5):567-573.
    View in: PubMed
    Score: 0.008
  152. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism Relat Disord. 2018 07; 52:83-89.
    View in: PubMed
    Score: 0.008
  153. Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life. Mov Disord. 2018 05; 33(5):742-749.
    View in: PubMed
    Score: 0.008
  154. Telemedicine Use for Movement Disorders: A Global Survey. Telemed J E Health. 2018 12; 24(12):979-992.
    View in: PubMed
    Score: 0.008
  155. Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. Mov Disord. 2018 03; 33(3):499-500.
    View in: PubMed
    Score: 0.008
  156. Validation study of the hoehn and yahr scale included in the MDS-UPDRS. Mov Disord. 2018 04; 33(4):651-652.
    View in: PubMed
    Score: 0.008
  157. Rating scales for cognition in Huntington's disease: Critique and recommendations. Mov Disord. 2018 02; 33(2):187-195.
    View in: PubMed
    Score: 0.008
  158. Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. Mov Disord. 2018 02; 33(2):208-218.
    View in: PubMed
    Score: 0.008
  159. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2017 Dec; 45:7-12.
    View in: PubMed
    Score: 0.008
  160. Response to letter by Saenz-Farret et al. on "Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations". Mov Disord. 2017 03; 32(3):482.
    View in: PubMed
    Score: 0.008
  161. Systematic review of severity scales and screening instruments for tics: Critique and recommendations. Mov Disord. 2017 03; 32(3):467-473.
    View in: PubMed
    Score: 0.008
  162. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.007
  163. Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation. Mov Disord. 2017 02; 32(2):274-277.
    View in: PubMed
    Score: 0.007
  164. Disability Rating Scales in Parkinson's Disease: Critique and Recommendations. Mov Disord. 2016 10; 31(10):1455-1465.
    View in: PubMed
    Score: 0.007
  165. Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. Mov Disord. 2016 10; 31(10):1466-1478.
    View in: PubMed
    Score: 0.007
  166. Abolishing the 1-year rule: How much evidence will be enough? Mov Disord. 2016 11; 31(11):1623-1627.
    View in: PubMed
    Score: 0.007
  167. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 09; 31(9):1373-80.
    View in: PubMed
    Score: 0.007
  168. The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurol. 2016 05; 15(6):546-8.
    View in: PubMed
    Score: 0.007
  169. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9.
    View in: PubMed
    Score: 0.007
  170. Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations. Mov Disord. 2016 09; 31(9):1342-55.
    View in: PubMed
    Score: 0.007
  171. Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. Mov Disord. 2016 05; 31(5):625-31.
    View in: PubMed
    Score: 0.007
  172. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct; 30(12):1591-601.
    View in: PubMed
    Score: 0.007
  173. MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015 Oct; 30(12):1600-11.
    View in: PubMed
    Score: 0.007
  174. The Mini-OAKHQOL for knee and hip osteoarthritis quality of life was obtained following recent shortening guidelines. J Clin Epidemiol. 2016 Jan; 69:70-8.
    View in: PubMed
    Score: 0.007
  175. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.007
  176. Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests? Mov Disord. 2015 Mar; 30(3):402-6.
    View in: PubMed
    Score: 0.006
  177. The past, present, and future of telemedicine for Parkinson's disease. Mov Disord. 2014 Jun; 29(7):871-83.
    View in: PubMed
    Score: 0.006
  178. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord. 2014 Apr; 29(4):454-62.
    View in: PubMed
    Score: 0.006
  179. A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord. 2014 May; 29(6):743-9.
    View in: PubMed
    Score: 0.006
  180. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014 Feb; 71(2):141-50.
    View in: PubMed
    Score: 0.006
  181. Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example. J Parkinsons Dis. 2014; 4(3):395-404.
    View in: PubMed
    Score: 0.006
  182. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord. 2013 Dec; 28(14):1972-9.
    View in: PubMed
    Score: 0.006
  183. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord. 2013 Dec; 28(14):1980-6.
    View in: PubMed
    Score: 0.006
  184. Task force report: scales for screening and evaluating tremor: critique and recommendations. Mov Disord. 2013 Nov; 28(13):1793-800.
    View in: PubMed
    Score: 0.006
  185. Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord. 2014 Feb; 29(2):169-76.
    View in: PubMed
    Score: 0.006
  186. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord. 2013 Oct; 19(10):889-93.
    View in: PubMed
    Score: 0.006
  187. Dystonia rating scales: critique and recommendations. Mov Disord. 2013 Jun 15; 28(7):874-83.
    View in: PubMed
    Score: 0.006
  188. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord. 2013 Sep; 19(9):806-11.
    View in: PubMed
    Score: 0.006
  189. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
    View in: PubMed
    Score: 0.006
  190. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy. PLoS One. 2013; 8(3):e58403.
    View in: PubMed
    Score: 0.006
  191. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013 May; 28(5):668-70.
    View in: PubMed
    Score: 0.006
  192. Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol. 2012 Jul; 11(7):643-50.
    View in: PubMed
    Score: 0.005
  193. Validation of the Italian version of the Movement Disorder Society--Unified Parkinson's Disease Rating Scale. Neurol Sci. 2013 May; 34(5):683-7.
    View in: PubMed
    Score: 0.005
  194. Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia. Mov Disord. 2012 May; 27(6):727-34.
    View in: PubMed
    Score: 0.005
  195. Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2012 Mar; 18(3):230-3.
    View in: PubMed
    Score: 0.005
  196. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct; 26 Suppl 3:S2-41.
    View in: PubMed
    Score: 0.005
  197. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct; 26 Suppl 3:S42-80.
    View in: PubMed
    Score: 0.005
  198. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease. Mov Disord. 2012 Jan; 27(1):79-83.
    View in: PubMed
    Score: 0.005
  199. Health-related quality-of-life scales in Parkinson's disease: critique and recommendations. Mov Disord. 2011 Nov; 26(13):2371-80.
    View in: PubMed
    Score: 0.005
  200. The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. Mov Disord. 2011 Sep; 26(11):1985-92.
    View in: PubMed
    Score: 0.005
  201. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2011 May; 10(5):377-93.
    View in: PubMed
    Score: 0.005
  202. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010 Aug; 67(8):996-1001.
    View in: PubMed
    Score: 0.005
  203. Association between antipsychotics and body mass index when treating patients with tics. J Child Adolesc Psychopharmacol. 2010 Aug; 20(4):277-81.
    View in: PubMed
    Score: 0.005
  204. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010 Jun; 16(6):653-61.
    View in: PubMed
    Score: 0.005
  205. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord. 2010 May 15; 25(7):805-22.
    View in: PubMed
    Score: 0.005
  206. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
    View in: PubMed
    Score: 0.005
  207. Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet. 2010 Jan 15; 19(2):299-312.
    View in: PubMed
    Score: 0.005
  208. Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord. 2009 Sep 15; 24(12):1732-9.
    View in: PubMed
    Score: 0.005
  209. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
    View in: PubMed
    Score: 0.004
  210. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord. 2009 Feb 15; 24(3):336-43.
    View in: PubMed
    Score: 0.004
  211. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008 Nov 15; 23(15):2248-50.
    View in: PubMed
    Score: 0.004
  212. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
    View in: PubMed
    Score: 0.004
  213. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007 Dec; 22(16):2314-24.
    View in: PubMed
    Score: 0.004
  214. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord. 2007 Sep 15; 22(12):1689-707; quiz 1837.
    View in: PubMed
    Score: 0.004
  215. The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol. 2007 May; 66(5):329-36.
    View in: PubMed
    Score: 0.004
  216. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol. 2007 Apr; 66(4):251-7.
    View in: PubMed
    Score: 0.004
  217. Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. Arch Neurol. 2007 Feb; 64(2):261-5.
    View in: PubMed
    Score: 0.004
  218. Neuropathic features in fragile X premutation carriers. Am J Med Genet A. 2007 Jan 01; 143A(1):19-26.
    View in: PubMed
    Score: 0.004
  219. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006 Dec; 21(12):2078-81.
    View in: PubMed
    Score: 0.004
  220. Gilles de la Tourette syndrome: patient's knowledge and concern of adverse effects. Mov Disord. 2006 Feb; 21(2):248-52.
    View in: PubMed
    Score: 0.004
  221. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb; 63(2):210-6.
    View in: PubMed
    Score: 0.004
  222. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006 Jan 10; 66(1):93-8.
    View in: PubMed
    Score: 0.004
  223. Movement disorders associated with encephalitis lethargica: a video compilation. Mov Disord. 2006 Jan; 21(1):1-8.
    View in: PubMed
    Score: 0.003
  224. Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
    View in: PubMed
    Score: 0.003
  225. Transcultural comparison of psychogenic movement disorders. Mov Disord. 2005 Oct; 20(10):1343-5.
    View in: PubMed
    Score: 0.003
  226. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord. 2005 Feb; 20(2):130-40.
    View in: PubMed
    Score: 0.003
  227. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
    View in: PubMed
    Score: 0.003
  228. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
    View in: PubMed
    Score: 0.003
  229. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
    View in: PubMed
    Score: 0.003
  230. The origins of scientific cinematography and early medical applications. Neurology. 2004 Jun 08; 62(11):2082-6.
    View in: PubMed
    Score: 0.003
  231. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol. 2004 Mar-Apr; 27(2):58-62.
    View in: PubMed
    Score: 0.003
  232. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15; 12(24):3259-67.
    View in: PubMed
    Score: 0.003
  233. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003 Sep; 54(3):403-14.
    View in: PubMed
    Score: 0.003
  234. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.003
  235. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003 May; 18(5):467-86.
    View in: PubMed
    Score: 0.003
  236. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol. 2003 May; 53(5):624-9.
    View in: PubMed
    Score: 0.003
  237. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003 Apr; 72(4):804-11.
    View in: PubMed
    Score: 0.003
  238. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. 2002 May 04; 359(9317):1589-98.
    View in: PubMed
    Score: 0.003
  239. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002 Apr; 70(4):985-93.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.